{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:03Z","timestamp":1789535043644,"version":"build-2803163510"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Lipoprotein(a) [Lp(a)] is a predominantly genetically determined lipoprotein whose concentration is generally stable over time, although clinically relevant within-person variation can occur. Elevated concentrations affect about one in five people. It has emerged as one of the most important causal contributors to the residual cardiovascular risk that persists despite effective LDL-cholesterol lowering in the statin era, and it is also causally implicated in calcific aortic valve stenosis. For decades Lp(a) was measurable yet effectively untreatable, because conventional lipid-lowering therapies do not reduce it to a clinically meaningful degree. Two practical obstacles further constrain its clinical use. Analytical standardization is incomplete: mass and molar units are not interchangeable, and some immunoassays are biased by apolipoprotein(a) isoform size. Real-world screening rates also remain very low, despite a guideline consensus on once-in-a-lifetime testing. This picture is now changing rapidly. RNA-targeted agents, comprising antisense oligonucleotides and small interfering RNAs, together with a first oral small-molecule inhibitor, lower Lp(a) by about 65% to more than 95%, differing in mechanism, route of administration, dosing interval and durability. Two questions remain open: how large an absolute reduction is needed for clinical benefit (the threshold hypothesis), and whether lowering Lp(a) reduces major adverse cardiovascular events at all. Several cardiovascular outcomes trials are now testing these questions directly. They include Lp(a)HORIZON, OCEAN(a)-Outcomes, and ACCLAIM-Lp(a), together with a dedicated aortic-valve trial, and the first readouts are anticipated. Framing Lp(a) as the residual cardiovascular risk target of the statin era, this review integrates measurement, screening, risk stratification, current management, and emerging targeted therapies into a single clinical and pharmacological roadmap for the outcomes-trial era.<\/jats:p>","DOI":"10.3389\/fphar.2026.1938864","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:04Z","timestamp":1789532944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) in the statin era: from risk marker to therapeutic target"],"prefix":"10.3389","volume":"17","author":[{"given":"Rongshen","family":"Hong","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Liu","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Li","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Liu","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Xie","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pcad.2025.03.001","article-title":"Waist to hip ratio modifies the cardiovascular risk of lipoprotein(a): insights from MESA","volume":"89","author":"Ahmad","year":"2025","journal-title":"Prog. Cardiovasc Dis."},{"key":"B2","volume-title":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(A) Reduction (OCEAN(a)) \u2014 Outcomes Trial. Clinicaltrials.Gov Identifier: NCT05581303","year":""},{"key":"B3","volume-title":"A Study of Olpasiran in Participants Without Prior Myocardial Infarction or Stroke (OCEAN(a)-PreEvent). Clinicaltrials.Gov Identifier: NCT07136012","year":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.maturitas.2017.02.009","article-title":"The effect of hormone replacement therapy and tibolone on lipoprotein(a) concentrations in postmenopausal women: a systematic review and meta-analysis","volume":"99","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1074\/jbc.M309414200","article-title":"Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly","volume":"279","author":"Becker","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e031255","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive Statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J. Clin. Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e946","DOI":"10.1016\/j.jacl.2024.08.012","article-title":"Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease","volume":"18","author":"Burvill","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1515\/cclm-2026-0149","article-title":"On the cusp of global lipoprotein(a) standardization","volume":"64","author":"Cobbaert","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","article-title":"Discovery of potent small-molecule inhibitors of lipoprotein(a) formation","volume":"629","author":"Diaz","year":"2024","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtm.2022.10.009","article-title":"LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: a proof-of-concept study","volume":"27","author":"Doerfler","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B24","volume-title":"Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults with Elevated Lipoprotein(A) (MOVE-Lp(a)). Clinicaltrials.Gov Identifier: NCT07157774","year":""},{"key":"B25","volume-title":"A Study of Lepodisiran in Participants with Elevated Lipoprotein(A) at High Risk for Cardiovascular Events (ACCLAIM-Lp(a)). Clinicaltrials.Gov Identifier: NCT06292013","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"101441","DOI":"10.1016\/j.jacadv.2024.101441","article-title":"Utilizing the electronic health record to evaluate lipoprotein(a) testing within a large regional health system","volume":"4","author":"Faridi","year":"2024","journal-title":"JACC Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/eurheartj\/ehae652","article-title":"Within-person stability of lipoprotein(a) concentration","volume":"46","author":"Ghouse","year":"2025","journal-title":"Eur. Heart J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0378-1119(97)00657-4","article-title":"The number of kringle IV repeats 3-10 is invariable in the human apo(a) gene","volume":"208","author":"Haibach","year":"1998","journal-title":"Gene"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein(a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1758366","DOI":"10.3389\/fcvm.2026.1758366","article-title":"Efficacy and safety of lipoprotein(a)-targeted therapeutics: a systematic review and network meta-analysis","volume":"13","author":"Hu","year":"2026","journal-title":"Front. Cardiovasc Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"19819","DOI":"10.1016\/S0021-9258(19)36587-1","article-title":"Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100","volume":"268","author":"Koschinsky","year":"1993","journal-title":"J. Biol. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2174\/0929867324666170120155412","article-title":"Lipoprotein(a) evolution: possible benefits and harm. Genetic and non-genetic factors influencing its plasma levels","volume":"24","author":"Kostakou","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European atherosclerosis society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The brussels international declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"","journal-title":"J. Am. Coll. Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"","journal-title":"Eur. Heart J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2021.11.053","article-title":"Measurement of lipoprotein(a): a once in a lifetime opportunity","volume":"79","author":"Marcovina","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"100239","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J. Lipid Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"120447","DOI":"10.1016\/j.atherosclerosis.2025.120447","article-title":"Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis","volume":"409","author":"Morton","year":"2025","journal-title":"Atherosclerosis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"","journal-title":"JAMA"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"","journal-title":"JAMA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"B68","volume-title":"Assessing the Impact of Lipoprotein(A) Lowering with Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients with CVD (Lp(A)Horizon). Clinicaltrials.Gov Identifier: NCT04023552","year":""},{"key":"B69","volume-title":"A Study of Pelacarsen in Patients with Calcific Aortic Valve Stenosis (Lp(A)Frontiers CAVS). Clinicaltrials.Gov Identifier: NCT05646381","year":""},{"key":"B70","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1093\/eurheartj\/ehag073","article-title":"Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial","volume":"47","author":"Parhofer","year":"2026","journal-title":"Eur. Heart J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1021\/bi010964i","article-title":"Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10","volume":"41","author":"Rahman","year":"2002","journal-title":"Biochemistry"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MOL.0000000000000753","article-title":"The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk","volume":"32","author":"Reyes-Soffer","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/clinchem\/hvac204","article-title":"Development of an LC-MRM-MS-based candidate reference measurement procedure for standardization of serum apolipoprotein(a) tests","volume":"69","author":"Ruhaak","year":"2023","journal-title":"Clin. Chem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e003354","DOI":"10.1161\/CIRCGEN.120.003354","article-title":"Associations of genetically predicted Lp(a) (lipoprotein[a]) levels with cardiovascular traits in individuals of European and African ancestry","volume":"14","author":"Satterfield","year":"2021","journal-title":"Circ. Genom Precis. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s0021-9150(97)00217-7","article-title":"Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians","volume":"136","author":"Thillet","year":"1998","journal-title":"Atherosclerosis"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"","journal-title":"Eur. Heart J."},{"key":"B92","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"","journal-title":"N. Engl. J. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1515\/cclm-2026-0130","article-title":"Analytical validation of an IFCC-endorsed mass spectrometry-based semi-automated reference measurement procedure for global standardization of serum apolipoprotein(a)","volume":"64","author":"van Neer","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"13","author":"Wilson","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1938864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:06Z","timestamp":1789532946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1938864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":97,"alternative-id":["10.3389\/fphar.2026.1938864"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1938864","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1938864"}}